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Abstract
AIM: To investigate the prevalence of significant liver 
fibrosis assessed using transient elastography (TE) and 
its predictors in asymptomatic general population.
METHODS: A total of 159 subjects without chronic 
viral hepatitis who underwent comprehensive medical 
health check-up between January 2012 and July 2012 
were prospectively recruited. Significant liver fibrosis 
was defined as liver stiffness value > 7.0 kPa.
RESULTS: The mean age and body mass index (BMI) 
of the study population (men 54.7%) was 56.0 years 
and 24.3 kg/m2. Among the study subjects, 11 (6.9%) 
showed significant liver fibrosis. On univariate analysis, 
BMI, alanine aminotransferase (ALT), homeostasis 
model assessment of insulin resistance, carotid intimal 
media thickness (IMT), number of calcified plaques on 
carotid ultrasound, and visceral fat area on computed 
tomography were significantly higher in subjects with 
significant liver fibrosis than in those without (all P  < 
0.05). However, on multivariate analysis, BMI [odds 
ratio (OR) =1.487; P  = 0.045], ALT (OR = 1.078; P  = 
0.014), carotid IMT (OR = 3.244; P  = 0.027), and the 
number of calcified carotid plaques (OR = 1.787; P  = 
0.031) were independent predictors of significant liver 
fibrosis. 
CONCLUSION: The prevalence of significant liver 
fibrosis assessed using TE was 6.9% in apparently 
healthy subjects. High BMI, high ALT, thicker carotid 
IMT, and higher numbers of calcified carotid plaques 
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were independently associated with the presence of 
significant liver fibrosis. 
Key words: Transient elastography; Healthy subjects; 
Fibroscan; Liver fibrosis; Non-alcoholic fatty liver di-
sease; Non-alcoholic steatohepatitis; Body mass index; 
Alanine aminotransferase; Carotid intimal medial th-
ickness; Carotid artery plaque
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Core tip: This is the first study which investigated the 
prevalence of significant liver fibrosis assessed using 
transient elastography and the correlation between 
comprehensive clinical metabolic parameters (body 
weight, visceral adiposity, insulin resistance, hepatic 
steatosis, and atherosclerosis) and the presence 
of significant liver fibrosis in asymptomatic general 
subjects. Finally, we found that the prevalence of 
significant liver fibrosis was fairly high (6.9%) and 
several factors including higher body mass index, 
higher alanine aminotransferase, thicker carotid intimal 
media thickness, and higher numbers of calcified 
carotid plaques on carotid sonography were significantly 
correlated to the risk of significant liver fibrosis.
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INTRODUCTION
Along with tremendous progress in antiviral agents and 
treatment strategies, a vigorous national vaccination 
program has resulted in a gradually decreasing 
prevalence of chronic viral hepatitis. Despite this, the 
socioeconomic cost for managing chronic liver diseases 
(CLDs) is continuously increasing every year in South 
Korea[1]. This phenomenon is attributed to other 
CLDs, particularly non-alcoholic fatty liver disease 
(NAFLD), which has an estimated prevalence of up 
to 45% in the Asian population[2].
The prognosis of CLDs, including chronic viral 
hepatitis and NAFLD, generally depends on the 
severity of liver fibrosis. However, a non-negligible 
fraction of patients with CLDs, especially NAFLD, 
remain asymptomatic and even show normal liver 
function tests[3,4]. This makes it difficult to prevent 
the progression of liver fibrosis to liver cirrhosis and 
hepatocellular carcinoma. Thus, accurate and timely 
determination of significant liver fibrosis is important 
to prevent progression of liver fibrosis in patients 
with CLDs and this effective screening will eventually 
reduce medical costs and improve prognosis.
Although liver biopsy has been regarded as the 
gold standard for detecting liver fibrosis, it is innately 
invasive and can lead to mortality, misdiagnosis 
due to interpretational variability, and sampling 
errors due to uneven fibrosis distribution within the 
liver parenchyma[5]. Recently, liver stiffness (LS) 
measurement using transient elastography (TE) 
has emerged as a promising noninvasive tool for 
assessing the degree of liver fibrosis. This technique 
is non-invasive, accurate, reproducible, convenient, 
and useful for serial measurement in various CLDs[6-9]. 
However, few studies have investigated TE for use 
identifying asymptomatic subjects with significant 
liver fibrosis by screening the population without 
overt liver diseases[10,11].
Hence, this study investigated whether TE can 
screen asymptomatic general population with-
out history of chronic viral hepatitis who received 
comprehensive medical health check-ups and 
identify subjects with significant liver fibrosis. In 
addition, we examined which factors other than 
chronic viral hepatitis are associated with the 
presence of significant liver fibrosis in this study 
population. 
MATERIALS AND METHODS
Patients
This study prospectively and consecutively included 
190 apparently healthy subjects who underwent a 
comprehensive medical health check-up including TE 
examination in Severance Hospital, Yonsei University 
College of Medicine, Seoul, Korea, between January 
2012 and July 2012. 
According to the exclusion criteria (Figure 1), 31 
patients were excluded; the remaining 159 patients 
were selected for statistical analysis. Five patients 
were excluded due to LS measurement failure (no 
valid shot) or unreliable LS value. An additional 26 
patients were excluded due to (1) chronic hepatitis 
B or C (n = 4); (2) missing laboratory test data (n = 
7); (3) missing carotid sonography data (n = 5); (4) 
missing fat computed tomography data (CT) (n = 
8); (6) right-sided heart failure (n = 0); or (7) lack 
of informed consent (n = 2). Baseline characteristics 
of the 31 excluded subjects were not statistically 
different from the 159 subjects included in this study 
(all P > 0.05, data not shown).
The study was performed in accordance with the 
ethical guidelines of the 1975 Declaration of Helsinki. 
Written informed consent was obtained from each 
participant or a responsible family member. This 
study was approved by the Institutional Review 
Board of Severance Hospital. 
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Laboratory and imaging studies
In addition to demographic data, a comprehensive 
medical health check-up with laboratory and imaging 
studies was performed on the same day of LS 
measurement using TE. Aspartate aminotransferase 
(AST) level, alanine aminotransferase (ALT) level, 
platelet count, fasting plasma glucose (FPG), Ho-
meostatsis Model Assessment of Insulin Resistance 
(HOMA-IR), and HbA1c were measured. HOMA-IR 
was calculated using the following formula: [(Fasting 
plasma insulin (μU/mL)*FPG (mg/dL))/405][12]. 
Imaging studies including fat CT and carotid sono-
graphy. Liver ultrasonography measured degree of 
hepatic steatosis as described previously[13].
Measurement of LS and controlled attenuation 
parameter 
The principles of LS and controlled attenuation 
parameter (CAP) measurement using TE have been 
described previously[14,15]. TE was performed by one 
experienced technician (> 10000 examinations) 
blind to clinical subject data. TE results are 
expressed as kilopascals (kPa) for LS and dB/m for 
CAP. The interquartile range (IQR) was defined as 
an index of the intrinsic variability of LS and CAP 
values corresponding to the interval of LS and CAP 
results containing 50% of the valid measurements 
between the 25th and 75th percentiles. The median 
value of successful measurements was selected as 
representative of the LS and CAP values of a given 
patient. As an indicator of variability, the ratio of 
the IQR of LS and CAP values to the median values 
(IQR/M and IQR/MCAP, respectively) was calculated. 
CAP was only calculated when the LS measurement 
was valid for the same signals, ensuring that liver 
ultrasonic attenuation was achieved simultaneously 
and in the same volume of liver parenchyma as the 
LS measurement. 
In this study, only procedures with at least ten 
valid measurements, a success rate of at least 60%, 
and an IQR/M of LS value < 0.3 were considered 
reliable and used for statistical analysis. Because the 
influence of IQR/MCAP on the accuracy of CAP has not 
been fully validated, IQR/MCAP was not adopted as a 
determinant for invalid CAP values.
Definition of significant liver fibrosis
In this study, a cut-off LS value of 7.0 kPa was 
defined to identify significant liver fibrosis. This value 
is based on a previous study from South Korea that 
proposed a normal LS range of 3.7-7.0 kPa in men 
and 3.3-6.8 kPa in women[16] and a study from Hong 
Kong that proposed the optimal cut-off LS value as 
7.0 kPa to diagnose significant liver fibrosis (≥ F2) 
in patients with NAFLD[17].
Statistical analysis
Results were expressed as mean ± SD, median 
(range), or n (%), as appropriate. The means or 
percentages of baseline characteristics between 
patients with and without significant fibrosis were 
compared using independent Student t-tests or 
Mann-Whitney U tests for continuous variables 
and χ 2 tests or Fisher’s exact tests for categorical 
variables. Univariate and multivariate logistic re-
gression analyses were performed for variables that 
were significantly different between groups with and 
without significant fibrosis. All statistical analyses 
were performed with standard procedures (SAS, 
version 18). Statistical significance was considered 
at P < 0.05.
RESULTS
Baseline characteristics
Baseline characteristics of the 159 study subjects 
are shown in Table 1. The mean age and body 
mass index (BMI) of the study population (87 men 
and 72 women) was 56.0 years and 24.3 kg/m2, 
respectively. The prevalence of obesity, defined 
as BMI > 25 kg/m2, was 41.5% (n = 66). Mean 
AST and ALT levels were 23.3 and 23.1 IU/L, 
respectively. On carotid sonography, mean intimal 
media thickness (IMT) was 0.75 mm. A carotid 
plaque was noted in 34 (21.4%) subjects, and the 
mean number of calcified carotid plaques was 0.48. 
Mean CAP and LS values were 248.3 dB/m and 4.7 
kPa, respectively.
Distribution of LS values
LS values were statistically similar between genders 
(4.5 kPa in men and 4.8 kPa in women, P = 0.360). 
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190 patients who received 
medical health check-up
 185 subjects with valid liver 
stiffness values
159 subjects were 
analyzed
(1) Failure of liver stiffness 
measurement (n  = 3)
(2) Invalid liver stiffness value (n  = 2)
(1) Chronic hepatitis B and C (n  = 4)
(2) Missing data in laboratory tests (n  = 7)
(3) Missing data in carotid Doppler 
sonography (n  = 5)
(4) Missing data in fat computed 
tomography (n  = 8)
(5) Right-sided heart failure (n  = 0)
(6) Not available informed consent (n  = 2)
Figure 1  Recruitment algorithm. A total of 190 consecutive subjects who 
received full medical health check-ups were recruited. Five patients were 
excluded due to inappropriate liver stiffness measurements. Of 185 subjects 
with valid liver stiffness values, 26 were excluded based on exclusion criteria. A 
total of 159 subjects were selected for final statistical analysis. 
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(age, BMI, ALT, HOMA-IR, visceral fat area on CT, 
number of calcified carotid plaques, and carotid 
IMT), BMI [odds ratio (OR) = 1.487; 95% confidence 
interval (CI): 1.009-2.193; P = 0.045], ALT (OR = 
1.078, 95%CI: 1.015-1.145; P = 0.014), carotid 
IMT (OR = 3.244, 95%CI: 1.140-9.234; P = 0.027), 
and number of calcified carotid plaques (OR = 1.787, 
95%CI: 1.055-3.026; P = 0.031) were selected as 
independent predictors of significant liver fibrosis 
based on positive correlations (Table 4).
Relative risk according to independent predictors
The study population was divided according to the 
medians of four independent factors (24.2 kg/m2 for 
BMI, 19 IU/L for ALT, 0.68 mm for carotid IMT, and 
one or more calcified carotid plaques) to calculate 
the relative risks between groups (Figure 3). 
Significant liver fibrosis was observed in ten of 79 
(12.7%) subjects with BMI ≥ 24.2 kg/m2, nine of 
78 (11.5%) subjects with ALT ≥ 19 IU/L, and ten of 
79 (12.7%) subjects with carotid IMT ≥ 0.68 mm. 
In contrast, significant liver fibrosis was noted in 
one of 80 (1.3%) subjects with BMI < 24.2 kg/m2 
(P = 0.005; OR = 11.4, 95%CI: 1.2-91.7), two of 
81 (2.5%) subjects with ALT < 19 IU/L (P = 0.030; 
OR = 5.2, 95%CI: 1.1-24.7), and one of 80 (1.3%) 
subjects with carotid IMT < 0.68 mm (P = 0.005; 
OR = 11.4, 95%CI: 1.4-91.7). In addition, the 
prevalence of significant liver fibrosis tended to be 
higher in subjects with calcified carotid plaques than 
in those without [5/35 (14.3%) vs 6/124 (4.8%); P 
= 0.065].
DISCUSSION
Despite the increasing popularity and reliability of 
LS measurement using TE to assess the degree 
of liver fibrosis in subjects with CLDs, only a few 
Western studies have shown the applicability of 
screening the general population[10,11]. Thus, we 
Among the study subjects, most subjects (n = 60, 
37.7%) had LS values of 4.0-4.9 kPa, whereas 11 
(6.9%) subjects had LS values higher than 7 kPa, 
indicating the presence of significant liver fibrosis 
(Figure 2). Characteristics of patients with significant 
fibrosis are shown in Table 2, published online. 
Factors associated with significant liver fibrosis 
Various characteristics were compared between 
subjects with and without significant liver fibrosis 
(Table 3). BMI, ALT, HOMA-IR, carotid IMT, number 
of calcified carotid plaques on carotid sonography, 
and visceral fat area on CT were significantly higher 
in subjects with significant liver fibrosis than in those 
without (27.5 vs 24.1 kg/m2; 32.3 vs 22.2 IU/L; 
2.9 vs 1.7; 1.4 vs 0.7 mm; 1.5 vs 0.4, and 171.5 
vs 107.2 cm2, respectively; all P < 0.05). CAP value 
was elevated in patients with significant liver fibrosis 
but failed to show significant differences between 
the groups.
Independent factors associated with significant liver 
fibrosis
On multivariate logistic regression analysis using 
variables that were significant in univariate analysis 
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Table 1  Baseline characteristics of study population (n  = 
159)
Variables Values
Demographic variables
   Age, yr   56.0 ± 10.6
   Male gender 87 (54.7)
   Body mass index, kg/m2 24.3 ± 3.1
   Diabetes mellitus 19 (11.9)
   Hypertension 40 (25.2)
   Daily alcohol intake, mg   15.4 ± 30.5
Laboratory variables
 Aspartate aminotransferase, IU/L 23.3 ± 8.5
   Alanine aminotransferase, IU/L   23.1 ± 12.2
   Platelet count, 109/L 235.5 ± 57.9
   Fasting plasma glucose, mg/dL 100.5 ± 24.5
   HOMA-IR   1.84 ± 1.35
   HbA1c, %   6.0 ± 0.7
Imaging variables
   Severe fatty liver on sonography 30 (18.9)
   Carotid sonography
      Intimal media thickness, mm   0.75 ± 0.57
      Presence of carotid plaque 34 (21.4)
      Calcified carotid plaque, n   0.48 ± 1.13
   Computed tomography
      Visceral fat area, cm2 112.4 ± 54.8
   Transient elastography
      Controlled attenuation parameter, dB/m 248.3 ± 44.4
         Interquartile rangeCAP, dB/m   35.91 ± 13.56
         Interquartile range/medianCAP   0.16 ± 0.06
      Liver stiffness value, kPa   4.7 ± 2.2
         Interquartile rangeLS, kPa   0.52 ± 0.21
         Interquartile range/medianLS   0.13 ± 0.06
Values are expressed as the mean ± SD (range) or n (%). HOMA-IR: 
Homeostasis model assessment of insulin resistance; HbA1c: Glycated 
hemoglobin; CAP: Controlled attenuation parameter; LS: Liver stiffness.
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Figure 2  Distribution of liver stiffness values. Among study participants, 
significant liver fibrosis (> 7 kPa) was observed in 11 (6.9%).
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tried to demonstrate the applicability of TE as a 
screening tool to identify subjects with potential 
significant liver fibrosis. For this aim, we included 
a cohort of apparently healthy native Korean sub-
jects without history of chronic viral hepatitis who 
underwent a comprehensive medical health check-
up. The prevalence of significant liver fibrosis 
was fairly high (6.9%) in this cohort. In addition, 
the associations between significant liver fibrosis 
and other clinical factors were investigated. BMI, 
ALT, carotid IMT, and number of calcified carotid 
plaques were identified as independent predictors 
of significant liver fibrosis. Although an exact 
comparison is not feasible due to differences in 
ethnicity and BMI, lack of histological information, 
and potential bias caused by reasons for the 
medical health check-up, the prevalence of sig-
nificant liver fibrosis in this study was similar to 
that of a previous French study (6.9% and 7.5%, 
respectively) that adopted 8 kPa as the cutoff value 
for screening the general population[11].
Regardless of etiology, significant liver fibrosis 
is associated with a risk of fibrosis progression 
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Table 2  Characteristics of patients with significant fibrosis
No. Age (yr) Gender BMI (kg/m2) Alcohol intake (g/d) ALT (IU/L) CAP (dB/m) Degree of fatty liver on US LS value (kPa)
1 47 F 24.7   0 11.0 259 Normal   7.1
2 69 F 28.1   0 46.0 348 Moderate   7.1
3 52 F 25.9 23 43.0 212 Mild   7.2
4 77 M 27.9   0 13.0 185 Normal   7.6
5 53 M 30.2 29 70.0 324 Moderate   7.6
6 68 M 26.5 38 42.0 274 Mild   7.8
7 77 M 33.9   0 35.0 281 Moderate   7.8
8 56 M 23.1 11 22.0 258 Mild   7.9
9 52 M 30.3   5 41.0 287 Mild   8.0
10 67 M 25.7   0 24.0 259 Mild 14.3
11 77 F 26.6   0 44.0 247 Mild 25.7
BMI: Body mass index; ALT: Alanine aminotransferase; CAP: Controlled attenuation parameter; US: Ultrasound; LS: Liver stiffness. 
Table 3  Comparison between patients with and without significant liver fibrosis (> 7 kPa)
Variables Patients without significant fibrosis 
[n  = 148 (93.1%), LS value ≤ 7 kPa]
Patients with significant fibrosis 
[n  = 11 (6.9%), LS value > 7 kPa]
P  value
Age, yr   55.5 ± 10.4   63.2 ± 11.5 NS 
Male gender 80 (54.1) 7 (63.6) NS
Body mass index, kg/m2 24.1 ± 3.0 27.5 ± 3.0 0.001 
Diabetes mellitus 17 (11.5) 2 (18.2) NS
Hypertension 38 (25.7) 2 (18.2) NS
Daily alcohol intake, mg   16.2 ± 31.7   11.0 ± 16.4 NS
Alanine aminotransferase, IU/L   22.2 ± 11.4   32.3 ± 17.1 0.024 
Platelet count, 109/L 235.6 ± 55.5 234.2 ± 92.0 NS
Fasting plasma glucose, mg/dL   99.7 ± 24.3 106.1 ± 24.9 NS
HOMA-IR   1.7 ± 1.2   2.9 ± 2.0 0.034 
HbA1c, %   6.0 ± 0.7   6.2 ± 0.6 NS
Presence of fatty liver on Sonography, n 53 (35.8%) 9 (81.8%) 0.004
Intimal media thickness, mm   0.7 ± 0.2   1.4 ± 2.1 0.011 
Presence of carotid plaque 31 (20.9) 3 (27.3) NS
Calcified carotid plaque, n   0.4 ± 1.0   1.5 ± 1.8 0.019 
Visceral fat area, cm2 107.2 ± 47.7 171.5 ± 93.0 0.002
Controlled attenuation parameter, dB/m 246.4 ± 43.8 266.7 ± 45.6 NS
Values are expressed as the mean ± SD (range), median (range), or n (%). NS: Not significant; LS: Liver stiffness; HOMA-IR: Homeostasis model assessment 
of insulin resistance; HbA1c: Glycated hemoglobin.
Table 4  Factors associated with significant liver fibrosis (> 7 
kPa)
Variable Univariate Multivariate
P  value Odds ratio 95%CI P  value
Age, yr 0.021 1.065 0.981-1.156 NS
Body mass index, kg/m2 0.001 1.487 1.009-2.193 0.045
Alanine aminotransferase, 
IU/L
0.010 1.078 1.015-1.145 0.014
HOMA-IR 0.013 0.950 0.555-1.626 NS
Visceral fat area, cm2 0.004 0.995 0.979-1.011 NS
Intimal media thickness, 
mm
0.195 3.244 1.140-9.234 0.027
Calcified carotid plaque, n 0.008 1.787 1.055-3.026 0.031
HOMA-IR: Homeostasis model assessment of insulin resistance; NS: Not 
significant.
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and poor prognosis[18,19]. Thus, it is of paramount 
importance to establish a screening strategy using non-
invasive tools such as TE to detect potential underlying 
significant liver fibrosis in the asymptomatic general 
population. This will eventually reduce the social 
burden of liver fibrosis while improving patients’ 
quality of life and survival by preventing disease 
progression. BMI, ALT, carotid IMT, and number of 
calcified carotid plaques, four independent predictors 
of significant liver fibrosis in this study, are generally 
known to have significant correlation to NAFLD[20-22], 
which is the leading cause of CLDs in the general 
population, with no evidence of chronic viral hepatitis 
worldwide[23-25]. This indicates that most subjects 
with significant liver fibrosis in the current study 
cohort may have NAFLD. Indeed, most patients with 
significant fibrosis (n = 9, 81.8%) showed more 
than mild fatty liver on ultrasonography. Of these, 6 
patients showed elevated ALT level.
To evaluate the relative risks of significant liver 
fibrosis, the study population was divided into two 
groups by BMI, ALT, carotid IMT, and number of 
calcified carotid plaques. Subjects with ALT higher 
than a cutoff value of 19 IU/L had significantly 
increased risk of significant liver fibrosis. This finding 
that subjects with normal ALT level are not completely 
free from the risk of significant liver fibrosis is 
consistent with the results of previous studies. 
Elevated ALT level, even within the current normal 
range (≤ 35-40 IU/L), has been associated with a 
risk of metabolic syndrome[26], CLDs[27], NASH[28], and 
mortality in the Korean population[29,30]. 
Subjects with BMI > 24.2 kg/m2 showed a higher 
prevalence of significant liver fibrosis. Weight gain 
has been shown to be closely related to liver fibrosis 
progression[19,31]. Although the exact mechanism for 
fibrotic progression in patients with NAFLD has not 
been fully recognized, obesity with a combination 
of insulin resistance and visceral adiposity causes 
hepatic lipid accumulation with various free fatty 
acid influx into the liver, up-regulation of hepatic 
lipogenic transcription factors, and inhibition of free 
fatty acid oxidation[32]. 
Interestingly, liver fibrosis had a significant re-
lationship with carotid IMT and the number of 
calcified carotid plaques in this study. In a previous 
study, the close association between the degree of 
NAFLD-related liver fibrosis and increased carotid 
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LS value ≤ 7.0 kPa
LS value > 7.0 kPa98.8%
1.3%
P  = 0.005
87.3%
12.7%
BMI < 24.2 kg/m2 BMI ≥ 24.2 kg/m2
97.5%
2.5%
P  = 0.030
88.5%
11.5%
ALT < 19 IU/L ALT ≥ 19 IU/L
BA
DC
98.8%
1.3%
P  = 0.005
87.3%
12.7%
IMT < 0.68 mm IMT ≥ 0.68 mm
95.2%
4.8%
P  = 0.065
85.7%
14.3%
Number of calcified 
carotid plaque = 0
Number of calcified 
carotid plaque ≥ 1
Figure 3  Proportion of subjects with significant liver fibrosis (> 7 kPa) according to four independent predictors. A: Body mass index; B: Alanine 
aminotransferase; C: Calcified carotid plaque; D: Number of calcified carotid plaques. The proportion of significant liver fibrosis was higher in subjects with high body 
mass index (≥ 24.2 kg/m2), high alanine aminotransferase (≥ 19 IU/L), and thicker IMT (≥ 0.68 mm) than in their counterparts (12.7% vs 1.3%, 11.5% vs 2.5%, 
12.7 vs 1.3%, respectively; All P < 0.05). Subjects with higher numbers of calcified carotid plaques (≥ 1) were prone to have significant liver fibrosis with borderline 
statistical significance (14.3% vs 4.8%, P = 0.065).
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IMT independent of metabolic syndrome and insulin 
resistance was reported[33]. This suggests that 
atherosclerosis can independently influence risk 
of liver fibrosis progression. Further studies are 
required to reveal how cardio- or cerebrovascular 
diseases due to atherosclerosis can be affected by 
liver fibrosis in subjects with NAFLD[19,24]. In addition, 
studies are needed to determine whether TE can 
be incorporated into screening protocols to identify 
high-risk subjects with cardio- or cerebrovascular 
diseases.
Age and prevalence of diabetes mellitus, which 
may have significant correlation with NAFLD or liver 
fibrosis[28], were higher in subjects with significant 
liver fibrosis, but the results were not statistically 
significant. These negative findings should be 
interpreted with caution due to a relatively small 
sample size. Unexpectedly, CAP values were not 
significantly different between groups, although 
we assumed that most subjects with significant 
liver fibrosis suffered from NAFLD and would have 
increased CAP values. This can be explained by 
that CAP, similar to other imaging modalities[15], 
cannot generally differentiate NASH which is related 
to fibrosis progression from simple steatosis, al-
though CAP does accurately reflect the amount of 
steatosis[34].
Our study still involves several unresolved issues. 
First, although previous studies[10,11] and our cur-
rent study have demonstrated the applicability of 
TE as a screening tool for diagnosing significant 
liver fibrosis in the general population, insufficient 
histological examinations for subjects assumed 
to have significant liver fibrosis can be a major 
limitation. Since significant hepatic dysfunction is 
rarely observed in the asymptomatic general po-
pulation, liver biopsies are not usually justified to 
confirm the histological diagnosis of liver disease. 
Thus, well-designed prospective studies that include 
a sufficient number of subjects with high LS value 
and histological evaluation are required. Second, 
we cannot be sure that the study participants are 
representative of the general population due to 
potential selection bias caused by recruiting subjects 
from health check-ups. However, because most 
baseline characteristics of the study subjects were 
similar to those in the general population, including 
daily alcohol intake[35], prevalence of hypertension 
and DM[36], carotid IMT thickness[37], and LS value[16], 
the results were not significantly influenced. Third, 
because this study was cross-sectional, further 
studies are needed to trace dynamic changes in LS 
values according to treatment interventions and to 
investigate the influence of LS changes on long-term 
clinical outcomes.
In conclusion, the prevalence of significant liver 
fibrosis assessed using TE was high in asymptomatic 
Korean general population, despite no evidence of 
underlying CLDs. High BMI, high ALT, thicker carotid 
IMT, and higher numbers of calcified carotid plaques 
were independently associated with the presence 
of significant liver fibrosis. Our results are helpful 
for identifying subjects who are at risk of significant 
asymptomatic liver fibrosis and for developing 
guidelines regarding the optimal utilization of TE in 
the general population.
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